Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab.

Autor: Koutroutsos K; Imperial College Kidney and Transplant Centre, London, UK. k.koutroutsos@windowslive.com.; Sussex Kidney Unit, Royal Sussex County Hospital, Eastern Road, Brighton, BN2 5BE, UK. k.koutroutsos@windowslive.com., Charif R; Imperial College Kidney and Transplant Centre, London, UK., Moran L; Department of Histopathology, Imperial Healthcare NHS Trust, London, UK., Moss J; Department of Histopathology, Imperial Healthcare NHS Trust, London, UK., Cook T; Department of Histopathology, Imperial Healthcare NHS Trust, London, UK., Roufosse C; Department of Histopathology, Imperial Healthcare NHS Trust, London, UK., Pusey C; Imperial College Kidney and Transplant Centre, London, UK., Taube D; Imperial College Kidney and Transplant Centre, London, UK., Loucaidou M; Imperial College Kidney and Transplant Centre, London, UK.
Jazyk: angličtina
Zdroj: Clinical and experimental nephrology [Clin Exp Nephrol] 2019 May; Vol. 23 (5), pp. 700-709. Date of Electronic Publication: 2019 Jan 14.
DOI: 10.1007/s10157-019-01690-0
Abstrakt: Background: Post-transplant focal segmental glomerulosclerosis (FSGS) is associated with renal allograft loss. Currently, optimal treatment remains controversial.
Methods: The aim of our study was to examine the efficacy and safety of therapeutic plasma exchange (TPE), and rituximab (RTX), in the management of post-transplant FSGS. The treatment protocol consisted of RTX and monthly cycles of 5 plasma exchanges for 6 months. We treated 10 transplant recipients with biopsy-proven post-transplant FSGS. Lastly, we compared the studied group to a historic control group of nine patients with post-transplant FSGS.
Results: 9 out of 10 patients achieved remission after the conclusion of treatment (4 complete and 5 partial), while 1 patient did not respond to treatment. During the follow-up period, there was one graft loss and one patient died while in remission from unrelated complications. There was a significant reduction in mean uPCR between diagnosis (517.4 ± 524.2 mg/mmol) and last follow-up (87 ± 121.6 mg/mmol) in the patients with sustained remission (p = 0.026). There was no significant decline in eGFR in the eight relapse-free responders at the end of follow-up. (54.4 ± 16.7 from 49.8 ± 20.4 ml/min) (p = 0.6) An increased response rate to the combined TPE and RTX treatment was demonstrated, when compared to a historic control group of nine patients with post-transplant FSGS, as only five out of nine patients achieved remission (two complete and three partial) in that group.
Conclusions: In this study, treatment with TPE and RTX appears to be safe, well tolerated and effective in the management of patients with post-transplant FSGS.
Databáze: MEDLINE
Externí odkaz: